TGRP — Nanopharmaceutics Share Price
Last trade - 00:00- $104.40m
- $103.36m
- $1.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 103.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -111.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 1.48 | 1.48 | n/a | n/a | 0.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The Company is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. The pipeline includes 10 clinical-stage proprietary and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infectious disease. Leveraging its expertise in nanoparticle and fine-particle formulations, the Company is focused on formulation development aimed at improving drug absorption and stability. Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity.
Directors
- Last Annual
- December 31st, 2017
- Last Interim
- September 30th, 2018
- Incorporated
- October 20th, 2015
- Public Since
- June 22nd, 2016
- No. of Employees
- 50
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 174,000,000
- Address
- K-2-8 2nd. Floor Kuchai Business Park, KUALA LUMPUR, 58200
- Web
- Phone
- +60 379878688
- Auditors
- Total Asia Associates
Similar to TGRP
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:22 UTC, shares in Nanopharmaceutics are trading at $0.60. This share price information is delayed by 15 minutes.
Shares in Nanopharmaceutics last closed at $0.60 and the price had moved by -16.69% over the past 365 days. In terms of relative price strength the Nanopharmaceutics share price has underperformed the S&P500 Index by -28.38% over the past year.
There is no consensus recommendation for this security.
Nanopharmaceutics does not currently pay a dividend.
Nanopharmaceutics does not currently pay a dividend.
Nanopharmaceutics does not currently pay a dividend.
To buy shares in Nanopharmaceutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.60, shares in Nanopharmaceutics had a market capitalisation of $104.40m.
Here are the trading details for Nanopharmaceutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: TGRP
Based on an overall assessment of its quality, value and momentum Nanopharmaceutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nanopharmaceutics. Over the past six months, its share price has underperformed the S&P500 Index by -11.57%.
As of the last closing price of $0.60, shares in Nanopharmaceutics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nanopharmaceutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Nanopharmaceutics' directors